

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM339155

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
UCB Pharma, S.A.		04/23/2015	societe anonyme (sa): BELGIUM
RECEIVING PARTY DATA			
Name:	UCB Biopharma SPRL		
Street Address:	Allee de la Recherche, 60 B-1070		
City:	Brussels		
State/Country:	BELGIUM		
Entity Type:	societe privee a responsabilite limitee: BELGIUM		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	2024253	ZYRTEC	
Registration Number:	2535836	ZYRTEC-D	
CORRESPONDENCE DATA			
Fax Number:	2027218250		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2027218200		
Email:	wlp@wenderoth.com		
Correspondent Name:	Wenderoth, Lind & Ponack, L.L.P.		
Address Line 1:	1030 15th Street, NW		
Address Line 2:	Suite 400 East		
Address Line 4:	Washington, D.C. 20005		
ATTORNEY DOCKET NUMBER:	TM00-105 & TM93-0109		
NAME OF SUBMITTER:	Christopher S. Adkins		
SIGNATURE:	/Christopher S. Adkins/		
DATE SIGNED:	04/23/2015		
Total Attachments: 2			
source=2015 04 23 - ZYRTEC - TRADEMARK ASSIGNMENT#page1.tif			
source=2015 04 23 - ZYRTEC - TRADEMARK ASSIGNMENT#page2.tif			

OP \$65.00 2024253

TRADEMARK ASSIGNMENT

WHEREAS, UCB Pharma, S.A. (hereinafter "Assignor"), a société anonyme (sa) of Belgium, having its principal place of business at Allée de la Recherche, 60 B-1070, Brussels BELGIUM, owns the mark and registration thereof for U.S. Trademark Reg. No. 2,024,253 for the mark ZYRTEC in Class 5, and U.S. Reg. No. 2,535,836 for the mark ZYRTEC-D in Class 5 (hereinafter "the Marks"), as depicted in **Schedule A**; and

WHEREAS, UCB Biopharma SPRL (hereinafter "Assignee"), société privée à responsabilité limitée of BELGIUM, having its principal place of business at Allée de la Recherche, 60 B-1070, Brussels, BELGIUM, desires to acquire the Marks as owner; and

WHEREAS, Assignee is the successor to the ongoing and existing portion of the business to which the Marks pertain; and

WHEREAS, Assignor desires to Assign and Assignee desires to acquire all right, title and interest in and to the Marks, registrations thereof and the ongoing and existing portions of the business to which the Marks pertain.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign to Assignee all right, title and interest in and to the Marks, including all common law rights, registrations or applications therefor, all rights of Assignor to petition, sue or otherwise seek and recover damages, profits and any other remedy (monetary, injunctive, declaratory or other), in the United States and anywhere, for any past, present or future infringement, conversion or misappropriation of, or other injury, offense, violation, breach of duty or wrong relating to the Marks, together with the goodwill of the Marks and the goodwill of the business associated with the Marks, and this assignment shall be deemed effective as of April 30, 2014.

IN WITNESS WHEREOF, Assignor executed this Assignment this 23rd day of April, 2015.

UCB Pharma, S.A.

By: 

Name:

Stéphane DROUIN
Proxy and Legal Representative

Title:

SCHEDULE A

<u>MARK</u>	<u>REGISTRATION NUMBER</u>	<u>REGISTRATION DATE</u>	<u>GOODS/SERVICES</u>
ZYRTEC (typed drawing form)	2,024,253	December 17, 1996	Antihistamines in Class 5
ZYRTEC-D (typed drawing form)	2,535,836	February 5, 2002	Pharmaceuticals preparations, i.e. antihistaminic and decongestant agents in Class 5